RBC Capital Reiterates Outperform on IDEAYA Biosciences, Maintains $45 Price Target
RBC Capital analyst Leonid Timashev reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and maintains $45 price target.
Last updated: 2026-11-19 06:15:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
IDEAYA Biosciences, Inc. (IDYA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $26.49, with a market capitalization of $2.65B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $26.02 to $42.68. This page covers its latest market performance, valuation, price trends and company information.
$2.65B | |
$27.07 | |
$27.67 | |
$26.03 | |
$27.40 | |
1.27M | |
921.85K | |
-- | |
$42.68 | |
$26.02 | |
-- | |
2026-09-30 |
IDEAYA Biosciences, Inc. (IDYA) last closed at $26.49 as of 2026-11-19 00:31:00, down 3.30% ($0.90) from the previous close of $27.40.
During the latest regular trading session, IDYA traded between $26.03 and $27.67, with a volume of 1.27M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, IDEAYA Biosciences, Inc. (IDYA) moved from $31.75 to $26.49, representing a decline of 16.56% ($5.26).
The stock traded between $26.02 and $32.91 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.03 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 2.8%
IDYA is currently trading at $26.49, placing it 2.8% of the way from its 52-week low of $26.02 to its 52-week high of $42.68. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 145 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to IDEAYA Biosciences, Inc. and IDYA stock.
RBC Capital analyst Leonid Timashev reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and maintains $45 price target.
Development candidate demonstrates encouraging preclinical activity in CDKN2A-deficienct tumor models as a monotherapy and in combination with inhibitors of RAS and MTAP, including IDEAYA's proprietary Phase 1 PRMT5
Eligible investors can buy real shares of IDEAYA Biosciences, Inc. (IDYA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to IDYA, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between IDYA shares and USD.
IDYA Shares to USD
1.00 IDYA shares = 26.493 USD
Calculations are estimates based on the latest available price and are for reference only.